nach oben

Erschienen in:

20.01.2021 | Original Contribution

Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study

verfasst von: Nuria Perez-Diaz-del-Campo, Bertha Araceli Marin-Alejandre, Irene Cantero, J. Ignacio Monreal, Mariana Elorz, José Ignacio Herrero, Alberto Benito-Boillos, Jose I. Riezu-Boj, Fermín I. Milagro, Josep A. Tur, J. Alfredo Martinez, Itziar Abete, M. Angeles Zulet

Erschienen in: European Journal of Nutrition | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Non-alcoholic fatty liver disease (NAFLD) is worldwide recognized as the most common cause of chronic liver disease. Current NAFLD clinical management relies on lifestyle change, nevertheless, the importance of the genetic make-up on liver damage and the possible interactions with diet are still poorly understood. The aim of the study was to evaluate the influence of the SH2B1 rs7359397 genetic variant on changes in body composition, metabolic status and liver health after 6-month energy-restricted treatment in overweight/obese subjects with NAFLD. In addition, gene-treatment interactions over the course of the intervention were examined.

Methods

The SH2B1 genetic variant was genotyped in 86 overweight/obese subjects with NAFLD from the FLiO study (Fatty Liver in Obesity study). Subjects were metabolically evaluated at baseline and at 6-months. Liver assessment included ultrasonography, Magnetic Resonance Imaging, elastography, a lipidomic test (OWL^®-test) and specific blood liver biomarkers. Additionally, body composition, general biochemical markers and dietary intake were determined.

Results

Both genotypes significantly improved their body composition, general metabolic status and liver health after following an energy-restricted strategy. Liver imaging techniques showed a greater decrease in liver fat content (− 44.3%, p < 0.001) and in serum ferritin levels (p < 0.001) in the carriers of the T allele after the intervention. Moreover, lipidomic analysis, revealed a higher improvement in liver status when comparing risk vs. no-risk genotype (p = 0.006 vs. p = 0.926, respectively). Gene-treatment interactions showed an increase in fiber intake and omega-3 fatty acid in risk genotype (p interaction = 0.056 and p interaction = 0.053, respectively), while a significant increase in MedDiet score was observed in both genotype groups (p = 0.020). Moreover, no-risk genotype presented a relevant decrease in hepatic iron as well as in MUFA intake (p = 0.047 and p = 0.034, respectively).

Conclusion

Subjects carrying the T allele of the rs7359397 polymorphism may benefit more in terms of hepatic health and liver status when prescribed an energy-restricted treatment, where a Mediterranean dietary pattern rich in fiber and other components such as omega-3 fatty acids might boost the benefits.

Trial registration

The Fatty Liver in Obesity was approved by the Research Ethics Committee of the University of Navarra and retrospectively registered (NCT03183193; www.clinicaltrials.gov); June 2017.

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L (2018) Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 24:3361–3373. https://doi.org/10.3748/wjg.v24.i30.3361CrossRefPubMedPubMedCentral

Younossi ZM (2019) Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 70:531–544. https://doi.org/10.1016/j.jhep.2018.10.033CrossRefPubMed

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004CrossRef

Recaredo G, Marin-Alejandre BA, Cantero I, Monreal JI, Herrero JI, Benito-Boillos A, Elorz M, Tur JA, Martínez JA, Zulet MA et al (2019) Association between different animal protein sources and liver status in obese subjects with non-alcoholic fatty liver disease: Fatty Liver in Obesity (FLiO) Study. Nutrients. 11:2359. https://doi.org/10.3390/nu11102359CrossRefPubMedCentral

Taliento AE, Dallio M, Federico A, Prati D, Valenti L (2019) Novel insights into the genetic landscape of nonalcoholic fatty liver disease. IJERPH 16:2755. https://doi.org/10.3390/ijerph16152755CrossRefPubMedCentral

Marin-Alejandre BA, Abete I, Cantero I, Riezu-Boj JI, Milagro FI, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J et al (2019) Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: a comparison with healthy controls. Nutrients. 11:322. https://doi.org/10.3390/nu11020322CrossRefPubMedCentral

Jennison E, Patel J, Scorletti E, Byrne CD (2019) Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med 95:314–322. https://doi.org/10.1136/postgradmedj-2018-136316CrossRef

Zhou J, Cai J, She Z, Li H (2019) Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol 25:1307–1326. https://doi.org/10.3748/wjg.v25.i11.1307CrossRefPubMedPubMedCentral

Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, Fu J (2019) Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci 15:265–276. https://doi.org/10.7150/ijbs.30121CrossRefPubMedPubMedCentral

10.

Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L (2019) Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD. Int J Environ Res Public Health. 16:3570. https://doi.org/10.3390/ijerph16193570CrossRefPubMedCentral

11.

Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69:2672–2682. https://doi.org/10.1002/hep.30251CrossRefPubMed

12.

Perez-Diaz-del-Campo N, Abete I, Cantero I, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI et al (2020) Association of the SH2B1 rs7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease. Nutrients 12:1260. https://doi.org/10.3390/nu12051260CrossRefPubMedCentral

13.

Sookoian S, Pirola CJ (2019) Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Semin Liver Dis 39:124–140. https://doi.org/10.1055/s-0039-1679920CrossRefPubMed

14.

Rui L (2014) SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes. 5:511–526. https://doi.org/10.4239/wjd.v5.i4.511CrossRefPubMedPubMedCentral

15.

Ren D, Zhou Y, Morris D, Li M, Li Z, Rui L (2007) Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. J Clin Investig 117:397–406. https://doi.org/10.1172/JCI29417CrossRefPubMedPubMedCentral

16.

Sheng L, Liu Y, Jiang L, Chen Z, Zhou Y, Cho KW, Rui L (2013) Hepatic SH2B1 and SH2B2 regulate liver lipid metabolism and VLDL secretion in mice. PLoS ONE 8:1–10. https://doi.org/10.1371/journal.pone.0083269CrossRef

17.

Mansego ML, Milagro FI, Zulet MA, Martinez JA (2015) SH2B1 CpG-SNP is associated with body weight reduction in obese subjects following a dietary restriction program. Ann Nutr Metab 66:1–9. https://doi.org/10.1159/000368425CrossRefPubMed

18.

Flores A, Argetsinger LS, Stadler LKJ, Malaga AE, Vander PB, Desantis LC, Joe RM, Cline JM, Keogh JM, Henning E et al (2019) Crucial role of the SH2B1 PH domain for the control of energy balance. Diabetes 68:2049–2062. https://doi.org/10.2337/db19-0608CrossRefPubMedPubMedCentral

19.

Cheng Y, Duan C, Zhang C (2020) Biomedicine and pharmacotherapy new perspective on SH2B1: an accelerator of cancer progression. Biomed Pharmacother. 121:109651. https://doi.org/10.1016/j.biopha.2019.109651CrossRefPubMed

20.

Lange LA, Graff M, Lange EM, Young KL, Richardson AS, Mohlke KL, North KE, Harris KM, Gordon-Larsen P (2016) Evidence for association between SH2B1 gene variants and glycated hemoglobin in nondiabetic european american young adults: the add health study. Ann Hum Genet. 80:294–305. https://doi.org/10.1111/ahg.12165CrossRefPubMedPubMedCentral

21.

Meroni M, Longo M, Rustichelli A, Dongiovanni P (2020) Nutrition and genetics in NAFLD: the perfect binomium. Int J Mol Sci. 21:2986. https://doi.org/10.3390/ijms21082986CrossRefPubMedCentral

22.

Bullón-Vela V, Abete I, Tur JA, Pintó X, Corbella E, Martínez-González MA, Toledo E, Corella D, Macías M, Tinahones F et al (2020) Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. Nutrition. 71:110620. https://doi.org/10.1016/j.nut.2019.110620CrossRefPubMed

23.

Galarregui C, Zulet MA, Cantero I, Marín-Alejandre BA, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Abete I et al (2018) Interplay of glycemic index, glycemic load, and dietary antioxidant capacity with insulin resistance in subjects with a cardiometabolic risk profile. Int J Mol Sci 19:E3662. https://doi.org/10.3390/ijms19113662CrossRefPubMed

24.

Cantero I, Abete I, Monreal JI, Martinez JA, Zulet MA (2017) Fruit fiber consumption specifically improves liver health status in obese subjects under energy restriction. Nutrients. 9:667. https://doi.org/10.3390/nu9070667CrossRefPubMedCentral

25.

Rinella ME, Tacke F, Sanyal AJ, Anstee QM (2019) Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 71:823–833. https://doi.org/10.1016/j.jhep.2019.04.019CrossRefPubMed

26.

Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A (2019) The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines (Basel) 6:41. https://doi.org/10.3390/medicines6010041CrossRef

27.

Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Cuervo M, Goni L, Martinez JA (2019) Models integrating genetic and lifestyle interactions on two adiposity phenotypes for personalized prescription of energy-restricted diets with different macronutrient distribution. Front. Genet. 10:686. https://doi.org/10.3389/fgene.2019.00686CrossRefPubMedPubMedCentral

28.

de Luis DA, Izaola O, Primo D, Aller R, Ortola A, Gómez E, Lopez JJ (2018) The association of SNP276G>T at adiponectin gene with insulin resistance and circulating adiponectin in response to two different hypocaloric diets. Diabetes Res Clin Pract 137:93–99. https://doi.org/10.1016/j.diabres.2018.01.003CrossRefPubMed

29.

Martinez JA, Navas-Carretero S, Saris WH, Astrup A (2014) Personalized weight loss strategies—the role of macronutrient distribution. Nat. Rev. Endocrinol. 10:749–760. https://doi.org/10.1038/nrendo.2014.175CrossRefPubMed

30.

Kaliora AC, Kalafati IP, Gioxari A, Diolintzi A, Kokkinos A, Dedoussis GV (2018) A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. Eur J Nutr. 57:2227–2235. https://doi.org/10.1007/s00394-017-1499-7CrossRefPubMed

31.

Dongiovanni P, Valenti L (2017) A nutrigenomic approach to non-alcoholic fatty liver disease. Int J Mol Sci. 18:1534. https://doi.org/10.3390/ijms18071534CrossRefPubMedCentral

32.

Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI et al (2019) The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial. Nutrients. 11:2543. https://doi.org/10.3390/nu11102543CrossRefPubMedCentral

33.

Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A (2011) Endpoints and clinical trial design for nonalcoholi steatohepatitis. Hepatology. https://doi.org/10.1002/hep.24376CrossRefPubMed

34.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357. https://doi.org/10.1002/hep.29367CrossRefPubMed

35.

Fernández-Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toledo E, Perez-Bauer M, Martínez-González MA, Salas-Salvadó J, Martín-Moreno JM (2010) Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr. 103:1808–1816. https://doi.org/10.1017/S0007114509993837CrossRefPubMed

36.

Galmes-Panades AM, Konieczna J, Abete I, Colom A, Rosique-Esteban N, Zulet MA, Vázquez Z, Estruch R, Vidal J, Toledo E et al (2019) Lifestyle factors and visceral adipose tissue: results from the PREDIMED-PLUS study. PLoS ONE 14:e0210726. https://doi.org/10.1371/journal.pone.0210726CrossRefPubMedPubMedCentral

37.

Tudor-Locke C, Williams JE, Reis JP, Pluto D (2002) Utility of pedometers for assessing physical activity: convergent validity. Sport Med. 32:795–808. https://doi.org/10.2165/00007256-200232120-00004CrossRef

38.

Wang Q, Zheng D, Liu J, Fang L, Li Q (2018) Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study. Lipids Health Dis. 17:284. https://doi.org/10.1186/s12944-018-0932-0CrossRefPubMedPubMedCentral

39.

de la Iglesia R, Lopez-Legarrea P, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martinez JA, Zulet MA (2014) A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project. Br J Nutr. 111:643–652. https://doi.org/10.1017/S0007114513002778CrossRefPubMed

40.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6:33. https://doi.org/10.1186/1471-230X-6-33CrossRefPubMedPubMedCentral

41.

Cantero I, Elorz M, Abete I, Marin BA, Herrero JI, Monreal JI, Benito A, Quiroga J, Martínez A, Huarte MP et al (2019) Ultrasound/Elastography techniques, lipidomic and blood markers compared to magnetic resonance imaging in non-alcoholic fatty liver disease adults. Int J Med Sci. 16:75–83. https://doi.org/10.7150/ijms.28044CrossRefPubMedPubMedCentral

42.

Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K (2018) Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 20:1702–1709. https://doi.org/10.1111/dom.13285CrossRefPubMed

43.

Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA (2018) Association of the Gly482Ser PPARGC1A gene variant with different cholesterol outcomes in response to two energy-restricted diets in subjects with excessive weight. Nutrition. 47:83–89. https://doi.org/10.1016/j.nut.2017.10.008CrossRefPubMed

44.

Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA (2018) Differential lipid metabolism outcomes associated with ADRB2 gene polymorphisms in response to two dietary interventions in overweight/obese subjects. Nutr Metab Cardiovasc Dis. 28:165–172. https://doi.org/10.1016/j.numecd.2017.11.006CrossRefPubMed

45.

Younes R, Bugianesi E (2019) NASH in lean individuals. Semin Liver Dis. 39:86–95. https://doi.org/10.1055/s-0038-1677517CrossRefPubMed

46.

Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 7(4):313–324. https://doi.org/10.1016/S2213-8587(18)30154-2CrossRefPubMed

47.

Ramos-Lopez O, Milagro FI, Allayee H, Chmurzynska A, Choi MS, Curi R, De Caterina R, Ferguson LR, Goni L, Kang JX et al (2017) Guide for current nutrigenetic, nutrigenomic, and nutriepigenetic approaches for precision nutrition involving the prevention and management of chronic diseases associated with obesity. J Nutrigenet Nutrigenomics. 10:43–62. https://doi.org/10.1159/000477729CrossRefPubMed

48.

Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, Cipollone F, Sutton R, Vettor R et al (2019) Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. 16:3104. https://doi.org/10.3390/ijerph16173104CrossRefPubMedCentral

49.

Haupt A, Thamer C, Heni M, Machicao F, Machann J, Schick F, Stefan N, Fritsche A, Häring HU, Staiger H (2010) Novel obesity risk loci do not determine distribution of body fat depots: a whole-body MRI/MRS study. Obesity (Silver Spring). 18:1212–1217. https://doi.org/10.1038/oby.2009.413CrossRef

50.

Wang JZ, Cao HX, Chen JN, Pan Q (2018) PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases. 6:167–175. https://doi.org/10.12998/wjcc.v6.i8.167CrossRefPubMedPubMedCentral

51.

Handy DE, Castro R, Loscalzo J (2011) Epigenetic modifications: Basic mechanisms and role in cardiovascular disease. Circulation 123:2145–2156. https://doi.org/10.1161/circulationaha.110.956839CrossRefPubMedPubMedCentral

52.

Li Z, Zhou Y, Carter-Su C, Myers MG Jr, Rui L (2007) SH2B1 enhances leptin signaling by both Janus kinase 2 Tyr813 phosphorylation-dependent and-independent mechanisms. Mol Endocrinol. 21:2270–2281. https://doi.org/10.1210/me.2007-0111CrossRefPubMed

53.

Mirhafez SR, Farimani AR, Dehhabe M, Bidkhori M, Hariri M, Ghouchani BF, Abdollahi F (2019) Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial. J Gastrointestin Liver Dis. 28:183–189. https://doi.org/10.15403/jgld-179CrossRefPubMed

54.

Boutari C, Mantzoros CS (2020) Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 103:154028. https://doi.org/10.1016/j.metabol.2019.154028CrossRefPubMed

55.

Hohenester S, Christiansen S, Nagel J, Wimmer R, Artmann R, Denk G, Bischoff M, Bischoff G, Rust C (2018) Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol. 315:G329–G338. https://doi.org/10.1152/ajpgi.00044.2018CrossRefPubMed

56.

Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E (2018) Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. J Nutr Biochem. 58:28–36. https://doi.org/10.1016/j.jnutbio.2018.03.025CrossRefPubMed

57.

Eslamparast T, Tandon P, Raman M (2017) Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. Nutrients. 9:800. https://doi.org/10.3390/nu9080800CrossRefPubMedCentral

58.

Lee HJ, Jang HB, Kim HJ, Ahn Y, Hong KW, Cho SB, Kang JH, Park SI (2015) The dietary monounsaturated to saturated fatty acid ratio modulates the genetic effects of GCKR on serum lipid levels in children. Clin Chim Acta. 450:155–161. https://doi.org/10.1016/j.cca.2015.08.012CrossRefPubMed

59.

Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, Caprio S (2012) Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS ONE 7:e37827. https://doi.org/10.1371/journal.pone.0037827CrossRefPubMedPubMedCentral

60.

Hosseini-Esfahani F, Koochakpoor G, Daneshpour MS, Mirmiran P, Sedaghati-Khayat B, Azizi F (2017) The interaction of fat mass and obesity associated gene polymorphisms and dietary fiber intake in relation to obesity phenotypes. Sci Rep. 7:18057. https://doi.org/10.1038/s41598-017-18386-8CrossRefPubMedPubMedCentral

61.

Goni L, Riezu-Boj JI, Milagro FI, Corrales FJ, Ortiz L, Cuervo M, Martínez JA (2018) Interaction between an ADCY3 genetic variant and two weight-lowering diets affecting body fatness and body composition outcomes depending on macronutrient distribution: a randomized trial. Nutrients. 10:789. https://doi.org/10.3390/nu10060789CrossRefPubMedCentral

62.

Celis-Morales CA, Lyall DM, Gray SR, Steell L, Anderson J, Iliodromiti S, Welsh P, Guo Y, Petermann F, Mackay DF et al (2017) Dietary fat and total energy intake modifies the association of genetic profile risk score on obesity: evidence from 48 170 UK Biobank participants. Int J Obes. 41:1761–1768. https://doi.org/10.1038/ijo.2017.169CrossRef

63.

San-Cristobal R, Navas-Carretero S, Martínez-González MÁ, Ordovas JM, Martínez JA (2020) Contribution of macronutrients to obesity: implications for precision nutrition. Nat Rev Endocrinol. 16:305–320. https://doi.org/10.1038/s41574-020-0346-8CrossRefPubMed

64.

Yoganathan P, Karunakaran S, Ho MM, Clee SM (2012) Nutritional regulation of genome-wide association obesity genes in a tissue-dependent manner. Nutr Metab (Lond). 9:65. https://doi.org/10.1186/1743-7075-9-65CrossRefPubMedPubMedCentral

65.

Gutierrez-Aguilar R, Kim DH, Woods SC, Seeley RJ (2012) Expression of new loci associated with obesity in diet-induced obese rats: from genetics to physiology. Obesity (Silver Spring). 20:306–312. https://doi.org/10.1038/oby.2011.236CrossRef

66.

Malik IA, Wilting J, Ramadori G, Naz N (2017) Reabsorption of iron into acutely damaged rat liver: a role for ferritins. World J Gastroenterol. 23:7347–7358. https://doi.org/10.3748/wjg.v23.i41.7347CrossRefPubMedPubMedCentral

67.

Kell DB, Pretorius E (2014) Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 6:748–773. https://doi.org/10.1039/c3mt00347gCrossRefPubMed

68.

Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, Kis O, Fliss-Isakov N, Izkhakov E, Halpern Z et al (2014) Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol. 20:4382–4392. https://doi.org/10.3748/wjg.v20.i15.4382CrossRefPubMedPubMedCentral

69.

Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K et al (2019) Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther. 50:930–939. https://doi.org/10.1111/apt.15427CrossRefPubMed

70.

Umemura T, Joshita S, Hamano H, Yoshizawa K, Kawa S, Tanaka E, Ota M (2017) Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients. J Hum Genet. 62:963–967. https://doi.org/10.1038/jhg.2017.74CrossRefPubMed

71.

Heianza Y, Qi L (2017) Gene-diet interaction and precision nutrition in obesity. Int J Mol Sci. 18:787. https://doi.org/10.3390/ijms18040787CrossRefPubMedCentral

72.

Giuranna J, Volckmar AL, Heinen A, Peters T, Schmidt B, Spieker A, Straub H, Grallert H, Müller TD, Antel J et al (2018) The effect of SH2B1 variants on expression of leptin- and insulin-induced pathways in murine hypothalamus. Obes Facts. 11:93–108. https://doi.org/10.1159/000486962CrossRefPubMedPubMedCentral

73.

Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, Willett WC, Hu FB (2016) Determinants and consequences of obesity. Am J Public Health. 106:1656–1662. https://doi.org/10.2105/AJPH.2016.303326CrossRefPubMedPubMedCentral

74.

Jiang L, Su H, Wu X, Shen H, Kim MH, Li Y, Myers MG Jr, Owyang C, Rui L (2020) Leptin receptor-expressing neuron Sh2b1 supports sympathetic nervous system and protects against obesity and metabolic disease. Nat Commun. 11:1517. https://doi.org/10.1038/s41467-020-15328-3CrossRefPubMedPubMedCentral

75.

Duan C, Li M, Rui L (2004) SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem. 279:43684–43691. https://doi.org/10.1074/jbc.M408495200CrossRefPubMed

76.

Hosseini-Esfahani F, Koochakpoor G, Daneshpour MS, Sedaghati-Khayat B, Mirmiran P, Azizi F (2017) Mediterranean dietary pattern adherence modify the association between FTO genetic variations and obesity phenotypes. Nutrients 9:E1064. https://doi.org/10.3390/nu9101064CrossRefPubMed

77.

Serafim V, Chirita-Emandi A, Andreescu N, Tiugan DA, Tutac P, Paul C, Velea I, Mihailescu A, Șerban CL, Zimbru CG et al (2019) Single nucleotide polymorphisms in PEMT and MTHFR genes are associated with omega 3 and 6 fatty acid levels in the red blood cells of children with obesity. Nutrients. 11:2600. https://doi.org/10.3390/nu11112600CrossRefPubMedCentral

78.

Bullón-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pintó X, Corbella E, Martínez-González MA, Sayón-Orea C, Toledo E et al (2020) Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab. https://doi.org/10.1177/2042018820958298CrossRefPubMedPubMedCentral

Titel: Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study
verfasst von: Nuria Perez-Diaz-del-Campo
Bertha Araceli Marin-Alejandre
Irene Cantero
J. Ignacio Monreal
Mariana Elorz
José Ignacio Herrero
Alberto Benito-Boillos
Jose I. Riezu-Boj
Fermín I. Milagro
Josep A. Tur
J. Alfredo Martinez
Itziar Abete
M. Angeles Zulet
Publikationsdatum: 20.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 6/2021
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-020-02476-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Dietary patterns of Australian pre-schoolers and associations with haem and non-haem iron intakes

Reply to Tomoyuki Kawada, MD: “Red meat consumption and biological markers of metabolic disorders”

Effect of low-iron micronutrient powder (MNP) on the composition of gut microbiota of Bangladeshi children in a high-iron groundwater setting: a randomized controlled trial

Similar dietary regulation of IGF-1- and IGF-binding proteins by animal and plant protein in subjects with type 2 diabetes

Transgenerational supplementation with eicosapentaenoic acid reduced the metabolic consequences on the whole body and skeletal muscle in mice receiving an obesogenic diet